Recent advances of dendrimers as multifunctional nano-carriers to combat breast cancer
- PMID: 34087355
- DOI: 10.1016/j.ejps.2021.105890
Recent advances of dendrimers as multifunctional nano-carriers to combat breast cancer
Abstract
Breast Cancer (BC) is a highly heterogeneous malignant carcinoma that is the most frequently occurring cancer in women. The major types of BC are luminal A, basal-like, luminal B, Human Epidermal Growth Factor Receptor 2 (HER2) positive/ Estrogen Receptor (ER) negative, and Triple-Negative BC (TNBC). The conventional therapies against BC include various chemotherapeutic agents in different combinations. Along with the chemotherapeutic drugs, alternatives like hormonal therapy, radiation, and nanotechnology are emerging fields in treating breast carcinoma. Dendrimers are three-dimensional hyperbranched nanosized structures that deal with the toxicity and resistance of chemotherapeutic agents in BC. These nanocarriers can carry drugs on the surface as well as inside the cavity to the desired site. Dendrimers have high loading capacity and exhibit targeted delivery of drugs resulting in reduced side effects. The current review discusses the utilization of dendrimers for treating BC and conquering the limitations of multidrug resistance.
Keywords: Breast cancer; Dendrimer; Drug delivery; Multidrug resistance; Nanotechnology.
Copyright © 2021. Published by Elsevier B.V.
Similar articles
-
A review of nanotechnology-based approaches for breast cancer and triple-negative breast cancer.J Control Release. 2020 Oct 10;326:628-647. doi: 10.1016/j.jconrel.2020.07.003. Epub 2020 Jul 10. J Control Release. 2020. PMID: 32653502 Review.
-
Recent Advances of Nanotechnology in the Diagnosis and Therapy of Triple- Negative Breast Cancer (TNBC).Curr Pharm Biotechnol. 2022;23(13):1581-1595. doi: 10.2174/1389201023666211230113658. Curr Pharm Biotechnol. 2022. PMID: 34967294 Review.
-
Nanotechnology-based siRNA delivery strategies for treatment of triple negative breast cancer.Int J Pharm. 2021 Aug 10;605:120835. doi: 10.1016/j.ijpharm.2021.120835. Epub 2021 Jun 28. Int J Pharm. 2021. PMID: 34197908 Review.
-
Proteomics as a Guide for Personalized Adjuvant Chemotherapy in Patients with Early Breast Cancer.Cancer Genomics Proteomics. 2015 Nov-Dec;12(6):385-90. Cancer Genomics Proteomics. 2015. PMID: 26543084 Review.
-
Opportunities in combinational chemo-immunotherapy for breast cancer using nanotechnology: an emerging landscape.Expert Opin Drug Deliv. 2022 Mar;19(3):247-268. doi: 10.1080/17425247.2022.2044785. Epub 2022 Feb 28. Expert Opin Drug Deliv. 2022. PMID: 35184620
Cited by
-
Nanoparticle-Mediated Immunotherapy in Triple-Negative Breast Cancer.ACS Biomater Sci Eng. 2024 Jun 10;10(6):3568-3598. doi: 10.1021/acsbiomaterials.4c00108. Epub 2024 May 30. ACS Biomater Sci Eng. 2024. PMID: 38815129 Free PMC article. Review.
-
Emerging innovations in cold plasma therapy against cancer: A paradigm shift.Drug Discov Today. 2022 Sep;27(9):2425-2439. doi: 10.1016/j.drudis.2022.05.014. Epub 2022 May 19. Drug Discov Today. 2022. PMID: 35598703 Free PMC article. Review.
-
Triphenylphosphine-Based Mitochondrial Targeting Nanocarriers: Advancing Cancer Therapy.Clin Pharmacol. 2025 Jun 10;17:119-141. doi: 10.2147/CPAA.S526895. eCollection 2025. Clin Pharmacol. 2025. PMID: 40524980 Free PMC article. Review.
-
Unravelling the enigma of siRNA and aptamer mediated therapies against pancreatic cancer.Mol Cancer. 2023 Jan 12;22(1):8. doi: 10.1186/s12943-022-01696-5. Mol Cancer. 2023. PMID: 36635659 Free PMC article. Review.
-
Unveiling innovative therapeutic strategies and future trajectories on stimuli-responsive drug delivery systems for targeted treatment of breast carcinoma.Naunyn Schmiedebergs Arch Pharmacol. 2024 Jun;397(6):3747-3770. doi: 10.1007/s00210-023-02885-9. Epub 2023 Dec 14. Naunyn Schmiedebergs Arch Pharmacol. 2024. PMID: 38095649 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous